ClinicalTrials.gg
TerminatedNCT04313725Updated Oct 28, 2026Results posted

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

An interventional study of Tangible Boost and Placebo in Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye and Sjogren's Syndrome, sponsored by Tangible Science. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Tangible Science · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Slow enrollment and difficulty getting patients to complete the study visits (significantly impacted by COVID-19 pandemic)
Updated Oct 28, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Stevens-Johnson Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Stevens-Johnson Syndrome · United States.

Enrollment
2nd of 10
28 · median 1
Started
2020
the only one that year
No phase
3 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Tangible Science

Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 3 with no phase, and was the 9th registered.

Stevens-Johnson Syndrome

40 studies on the registry are indexed under Stevens-Johnson Syndrome; 7 are open to participants now.

Browse Stevens-Johnson Syndrome studies →

Open to participants now

1 of the 11 studies in Stevens-Johnson Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stevens-Johnson Syndrome studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stevens-Johnson Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.

Hydra-PEG is a coating for soft and rigid contact lens, primarily composed of polyethylene glycol-based hydrogel, which is covalently bound to the surface of a contact lens. The Hydra-PEG coating is intended to improve wettability and comfort with contact lenses and is currently FDA approved on a number of contact lenses. For patients with Stevens Johnson Syndrome (SJS) (SS), or Graft versus Host disease (GVHD), diminished efficacy of the Hydra-PEG coating can lead to significant decline in satisfaction with the lenses over time. This is a prospective study to evaluate the efficacy of Tangible Boost, a monthly conditioning solution, to replenish the Hydra-PEG coating on rigid gas permeable contact lenses for patients with SJS, GVHD, and SS. Outcomes from this patient population will be compared to patients with dry eye disease.

03

Conditions studied

  • Stevens-Johnson Syndrome
  • Graft Versus Host Disease in Eye
  • Sjogren's Syndrome
  • Dry Eye

Keywords

  • contact lens care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written has been obtained prior to any study-related procedures taking place
  • Written documentation has been obtained in accordance with the relevant county and local privacy requirements, where applicable
  • Male or female
  • 18 years of age and older prior to the initial visit
  • Is a new or established wearer of PROSE lenses with optimized lens fit prior to enrollment in the study
  • Has been diagnosed with Dry Eye Syndrome, SJS, SS, or
  • In the opinion of the investigator, the subject has the ability to follow study instructions
  • In the opinion of the investigator, the subject has the ability to complete all study procedures and visits

Exclusion criteria

Exclusion Criteria:

  • aphakic (i.e., missing their natural lens inside the eye)
  • Is currently participating in any other type of eye-related clinical or research study
  • Is pregnant or nursing as reported by the subject
  • Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
  • Has a known and self-reported allergy to the following substances: polyethylene glycol, polyvinyl alcohol, triethanolamine, polyquaternium-1, or edetate disodium, which are components of the Tangible Boost and Hydra-PEG systems or care regimen.
  • Has had previous ocular surgery within the past 12 weeks
  • Adults unable to consent (including adults unable to read and understand English)
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Employees of BostonSight
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Boost

    Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.

    Device: Tangible Boost

  • Placebo comparator
    Placebo

    Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.

    Other: Placebo

Interventions

  • DeviceTangible Boost

    Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.

  • OtherPlacebo

    Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.

06

What researchers measure

Primary outcomes

  1. Visual Acuity

    LogMAR visual acuity

    Time frame: 3 months

  2. Visual Acuity

    LogMAR visual acuity

    Time frame: 6 months

  3. Contact Lens Comfort

    OSDI plus additional specific questions

    Time frame: 3 months

  4. Contact Lens Comfort

    OSDI plus additional specific questions

    Time frame: 6 months

  5. Ocular Surface Staining

    Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.

    Time frame: 3 months

  6. Ocular Surface Staining

    Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.

    Time frame: 6 months

  7. Tear Break up Time

    Seconds required for tear film to begin to break up

    Time frame: 3 months

  8. Tear Break up Time

    Seconds required for tear film to begin to break up

    Time frame: 6 months

Secondary outcomes

  1. Contact Lens Fit Characteristics

    Patients with substantial changes in apical clearance, limbal clearance, scleral landing evaluation

    Time frame: 6 months

07

Results

Posted Oct 28, 2026

Participant flow

The subject pool consisted of patients of the Boston Sight clinic. Interested patients were directed to the principal investigator or the study coordinator, who went over the study and asked the screening questions. Recruitment occurred from February 2020 to December 2022.

Participant flow — Overall Study
MilestoneBoostControl
Started1612
Completed86
Not completed86

Outcome measures

PrimaryVisual Acuity

LogMAR visual acuity

Time frame:
3 months
Reported as:
Mean · logMAR visual acuity units
Visual Acuity
logMAR visual acuity unitsBoostControl
Visual Acuity0.18 ± 0.210.17 ± 0.17
PrimaryVisual Acuity

LogMAR visual acuity

Time frame:
6 months
Reported as:
Mean · logMAR visual acuity units
Visual Acuity
logMAR visual acuity unitsBoostControl
Visual Acuity0.17 ± 0.240.21 ± 0.21
PrimaryContact Lens Comfort

OSDI plus additional specific questions

Time frame:
3 months
Reported as:
Mean · OSDI score
Contact Lens Comfort
OSDI scoreBoostControl
Contact Lens Comfort20.0 ± 9.919.8 ± 9.5
PrimaryContact Lens Comfort

OSDI plus additional specific questions

Time frame:
6 months
Reported as:
Mean · OSDI score
Contact Lens Comfort
OSDI scoreBoostControl
Contact Lens Comfort24.7 ± 10.418.4 ± 11.6
PrimaryOcular Surface Staining

Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.

Time frame:
3 months
Reported as:
Mean · units
Ocular Surface Staining
unitsBoostControl
Ocular Surface Staining2.1 ± 2.62.4 ± 2.1
PrimaryOcular Surface Staining

Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.

Time frame:
6 months
Reported as:
Mean · units
Ocular Surface Staining
unitsBoostControl
Ocular Surface Staining1.9 ± 2.43.7 ± 2.3
PrimaryTear Break up Time

Seconds required for tear film to begin to break up

Time frame:
3 months
Reported as:
Mean · seconds
Tear Break up Time
secondsBoostControl
Tear Break up Time4.9 ± 3.87.8 ± 4.4
PrimaryTear Break up Time

Seconds required for tear film to begin to break up

Time frame:
6 months
Reported as:
Mean · seconds
Tear Break up Time
secondsBoostControl
Tear Break up Time5.6 ± 4.87.3 ± 3.9
SecondaryContact Lens Fit Characteristics

Patients with substantial changes in apical clearance, limbal clearance, scleral landing evaluation

Time frame:
6 months
Reported as:
Count of participants · Participants
Contact Lens Fit Characteristics
ParticipantsBoostControl
Contact Lens Fit Characteristics00

Adverse events

Collected over From enrollment until last follow-up at 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boost0/11 (0%)0/11 (0%)1/11 (9.1%)
Control0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Most frequent other events
EventBoostControl
Lens intolerableEye disorders1/111/10

Baseline characteristics

No information available for patients lost to COVID or withdrawal prior to completion of Visit 1B.

Age, Categorical
Age, Categorical(Participants)BoostControlTotal
<=18 years000
Between 18 and 65 years7613
>=65 years448
Sex: Female, Male
Sex: Female, Male(Participants)BoostControlTotal
Female9615
Male246
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BoostControlTotal
Count of participants——0
Visual Acuity
Visual Acuity(logMAR units)BoostControlTotal
Mean0.24 ± 0.190.20 ± 0.240.22 ± 0.21
Contact Lens Comfort
Contact Lens Comfort(OSDI score)BoostControlTotal
Mean22.5 ± 15.337.3 ± 19.529.6 ± 18.6
Ocular Surface Staining
Ocular Surface Staining(units)BoostControlTotal
Mean2.0 ± 3.03.5 ± 3.02.7 ± 3.1
Tear break up time
Tear break up time(seconds)BoostControlTotal
Mean7.9 ± 5.18.3 ± 4.68.1 ± 4.8
08

Study locations

1 site
  • Boston Sight
    Needham, Massachusetts 02494, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jun 2023, 39 months.

Results were first posted in Oct 2026, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 18, 2020
StartActual
Feb 24, 2020
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Primary outcomes
2 edited, 2 description edited
What changed in the outcomes
  • EditedTear breakBreak up timeTimeTime frame: 3 months
  • EditedTear breakBreak up timeTimeTime frame: 6 months
  • DescriptionVisual Acuity: how it is measured was reworded
  • DescriptionVisual Acuity#2: how it is measured was reworded
Oct 28, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedContact lens fit characteristicsLens Fit CharacteristicsTime frame: 6 months
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 2 edited, 2 description edited
    What changed in the outcomes
    • EditedTear breakBreak up timeTimeTime frame: 3 months
    • EditedTear breakBreak up timeTimeTime frame: 6 months
    • DescriptionVisual Acuity: how it is measured was reworded
    • DescriptionVisual Acuity#2: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedContact lens fit characteristicsLens Fit CharacteristicsTime frame: 6 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04313725
Lead sponsor
Tangible Science
Collaborators
Boston Sight
Responsible party
Sponsor
First posted
Mar 18, 2020
Start date
Feb 24, 2020
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Karen Carrasquillo, OD, PhD
principal investigator · Boston Sight

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion